grant
Therapeutic targeting of a novel driver of prostate cancer progression.
Organization VA NORTHERN CALIFORNIA HEALTH CARE SYSLocation MATHER, UNITED STATESPosted 1 Jan 2019Deadline 31 Mar 2028
VANIHUS FederalResearch GrantFY2025ADRB2ADRB2 geneADRB2RADRBRAdenosine Cyclic Monophosphate-Dependent Protein KinasesAdrenergic AgentsAdrenergic DrugsAdrenergic ReceptorAdrenergic beta-AntagonistsAdrenergic beta-BlockersAdrenergicsAdrenoceptorsAffectAndrogen AntagonistsAndrogen ReceptorAnti-AndrogenAnti-Androgen AgentsAutomobile DrivingB2ARBeta-2 Adrenergic Receptor GeneBeta-2 Adrenoceptor GeneC-X-C Chemokine Receptor Type 4CD184 AntigenCXC-R4CXCR-4CXCR4CXCR4 ReceptorsCXCR4 geneCancer CauseCancer EtiologyCancersCatecholamine Receptor GeneCell Communication and SignalingCell LineageCell SignalingCellular biologyCessation of lifeChemokine (C-X-C Motif) Receptor 4Chemokine Receptor GeneChemokine, CXC Motif, Receptor 4ChromatinChromatin StructureClinicalClinical TreatmentClinical TrialsCouplingCyclic AMP-Dependent Protein KinasesD2S201EDataData SetDeathDevelopmentDiseaseDisorderDrug ReceptorsDrug TargetingDrug resistanceEctopic ExpressionEndocrine Gland SecretionEpinephrine ReceptorsFB22FamilyFoundationsFusinFutureGeneral PopulationGeneral PublicGeneralized GrowthGenesGeneticGenomic approachGrowthHM89HSY3RRHealthHistonesHormone ReceptorHormonesHumanIntracellular Communication and SignalingLAP3LCR1LESTRLESTR ReceptorLPS-Associated Protein 3Leukocyte-Derived Seven-Transmembrane Domain ReceptorLifeLigandsLipopolysaccharide-Associated Protein 3Malignant NeoplasmsMalignant TumorMalignant neoplasm of prostateMalignant prostatic tumorMediatingModelingModern ManMolecularNPY3RNPYRNPYRLNPYY3RNeuroendocrineNeuroendocrine Prostate CancerNeuroendocrine SystemNeurohumor ReceptorsNeuromediator ReceptorsNeuropeptide Y Receptor Y3Neuroregulator ReceptorsNeurosecretory SystemsNeurotransmitter ReceptorPDX modelPKAPatient derived xenograftPatientsPre-Clinical ModelPreclinical ModelsProstateProstate CAProstate CancerProstate GlandProstate Neuroendocrine NeoplasmProstate Neuroendocrine TumorProstate malignancyProstatic GlandProtein Kinase AReceptor ProteinReceptor SignalingResearch SpecimenResistanceRoleSDF-1 ReceptorSDF1/PBSF Receptor CXCR4SafetySignal TransductionSignal Transduction SystemsSignalingSignaling Factor Proto-OncogeneSignaling Pathway GeneSignaling ProteinSolidSpecimenSpleen Seven-Transmembrane-Segment ReceptorStromal Cell-Derived Factor 1 ReceptorTestingTherapeuticTherapeutic HormoneTherapeutic InterventionTissue GrowthVeteransXtandiadenoreceptoradvanced diseaseadvanced illnessadvanced prostate cancerandrogen inhibitorantagonismantagonistbeta blockerbeta-Adrenergic Blocking Agentsbeta-Adrenergic Receptor Blockadersbiological signal transductioncAMP-Dependent Protein Kinasescancer progenitorcancer progenitor cellscancer stem cellcancer stem like cellcancer typecell biologychemokine receptorchromatin remodelingclinical interventionclinical significanceclinical therapyclinically significantdevelopmentaldrivingdrug candidatedrug resistantenzalutamideepigenomicsfunctional genomicsgene synthesisgenetic approachgenetic strategygenomic effortgenomic strategyinhibitorinhibitor druginhibitor therapeuticinhibitor therapyinnovateinnovationinnovativeinsightintervention therapyknock-downknockdownmalignancymalignant progenitormalignant stem cellmembermenmilitary veteranneoplasm/cancernew drug targetnew druggable targetnew pharmacotherapy targetnew therapeutic targetnew therapy targetnovelnovel drug targetnovel druggable targetnovel pharmacotherapy targetnovel therapeutic targetnovel therapy targetoncogenic progenitoroncogenic stem cellsontogenypatient derived xenograft modelpharmacologicprogenitor like cancer cellprogramsprostate cancer cellprostate cancer progressionprostate tumor cellreceptorresistance to Drugresistance to therapyresistantresistant to Drugresistant to therapyresponsescRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsmall molecular inhibitorsmall moleculesmall molecule inhibitorsocial rolestem like cancer celltherapeutic candidatetherapeutic resistancetherapeutic targettherapeutically effectivetherapy resistanttreatment resistancetrial regimentrial treatmenttumortumor growthtumorigenicveteran population
Description preview
Advanced prostate cancers disproportionally affect veteran populations in the US. One
key feature of the advanced diseases is the development of anti-androgen receptor
therapy resistance through a mechanism of tumor lineage plasticity, which contributes to
the lethal progression of prostate cancer. However, the mechanisms underlying the
aberration…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click